Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in pcos patients
Recent studies on the pathophysiology of infertility have shown that oxidative stress (OS) can be one of the causal factors. The OS is, by definition, an imbalance between the production of reactive oxygen species and antioxidant defense systems. It seems that oxidative stress plays an important role in almost all phases of human reproduction. In fact, reactive oxygen species are involved in the modulation of a large spectrum of reproductive functions such as oocyte maturation, ovarian steroidogenesis, corpus luteum functions and are involved in the processes of fertilization, embryo development and pregnancy, but also in some diseases that cause infertility. Polycystic ovary syndrome (PCOS) has recently been associated with increased oxidative stress, often put in relation to the syndrome's typical metabolic disorder. Inositol is an intracellular mediator of insulin, currently much used as a therapeutic agent in PCOS. While its main action takes place via insulin sensitization, little is known about the possible effects of other disorders, such as oxidative stress, associated with PCOS.
Purpose of study was therefore to assess the effect of D-chiro-inositol on the state of oxidative stress in the follicular fluid of women with PCOS.
Materials and methods. Follicular fluids were obtained from women who have turned to the Center for Diagnosis and Treatment of Sterility of Obstetrics and Gynecology of the University Hospital of Siena and Modena diagnosed with PCOS. The women were treated with D-chiro-inositol (500 mg x 2 per day) for 3 months before being subjected to cycles of in vitro fertilization. The state of oxidative stress was measured by marking of free thiol groups of proteins in the follicular fluid with 3-(N-maleimidopropionyl)-biocytin.
Results. In our study we obtained a lesser presence of free thiol protein groups equal to 77.8% in the follicular fluid of women with PCOS not treated with D-chiro-inositol, compared to patients who instead have carried out such treatment.Conclusions. These results suggest that in PCOS women there is an increase of the oxidation of thiol groups of proteins follicular, correlated to a progressive increase of the oxidative stress and that the administration of D-chiro-inositol in patients with this disease seems to reduce the oxidation of thiol groups
Full Text:PDF (Українська)
Asuncion, M., Calvo, R.M., San Millan, J.L., et al. “A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.” J Clin Endocrinol Metab 85 (2000): 2434–8.
Azziz, R., Woods, K.S., Reyna, R., et al. “The prevalence and features of the polycystic ovary syndrome in an unselected population.” J Clin Endocrinol Metab 89 (2004): 2745–9.
Goodarzi, M.O., Quinones, M.J., Azziz, R., et al. “Polycystic ovary syndrome in Mexican- Americans: prevalence and association with the severity of insulin resistance.” Fertil Steril 84 (2005): 766–9.
Stein, I.F., Leventhal, M.L. “Amenorrhea associated with bilateral polycystic ovaries.” Am J Obstet Gynecol 29 (1935): 181–91.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. “Revised 2003 consensus on diagnostic criteria and long- term health risks related to polycystic ovary syndrome.” Fertil Steril 81 (2004): 19–25.
Kalro, B.N., Loucks, T.L., Berga, S.L. “Neuromodulation in polycystic ovary syndrome.” Obstet Gynecol Clin North Am 28 (2001): 35–62.
Rebar, R., Judd, H.L., Yen, S.S., et al. “Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.” J Clin Invest 57 (1976): 1320–9.
Berger, M.J., Taymor, M.L., Patton, W.C. “Gonadotropin levels and secretory patterns in patients with typical and atypical polycystic ovarian syndrome.” N England J Med 320 (1989): 559–65.
Dahlgren, E., Johansoon, S., Lindstedt, G., et al. “Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow up focusing on natural history and circulating hormones.” Fertil Steril 57 (1992): 505–13.
Talbott, E., Guzick, D., Clerici, A., et al. “Coronary heart disease risk factors in women with polycystic ovary syndrome.” Arterioscler Tromb Vasc Biol 15 (1995): 821–6.
Dunaif, A. “Insuline resistance and polycystic ovary syndrome: mechanism and implication for pathogenesis.” Endocr Rev 18 (1997): 774–800.
Amowitz, L.L., Sobel, B.E. “Cardiovascular consequences of polycystic ovary syndrome.” Endocrinol Metab Clin North Am 28 (1999): 439–58.
Franks, S., McCarthy, M.I., Hardy, K. “Development of polycystic ovary syndrome: involvement of genetic and environmental factors.” Int J Androl 29 (2006): 278–85.
Chang, R.J., Nakamura, R.M., Judd, H.L., Kaplan, S.A. “Insulin resistance in nonobese patients with polycystic ovarian disease.” J Clin Endocrinol Metab 57 (1983): 356–9.
Ciaraldi, T.P., El-Roeiy, A., Madar, Z., et al. “Cellular mechanisms of insulin resistance in polycystic ovarian syndrome.” J Clin Endocrinol Metab 75 (1982): 577–83.
Marsden, P.J., Murdoch, A., Taylor, R. “Severe impairment of insulin action in adipocytes from amenorrhoeic subjects with polycystic ovary syndrome.” Metabolism 43 (1994): 1536–42.
Morales, A.J., Laughlin, G.A., Butzow, T., et al. “Insulin, somatrotopic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common distinct features.” J Clin Endocrinol Metab 81 (1996): 2854–9.
Velazquez, E., Acosta, A., Mendoza, S.G. “Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.” Obstet Gynecol 90 (1997): 392–5.
De Leo, V., Musacchio, M.C., Morgante, G., et al. “Metformin treatment is effective in obese teenage girls with PCOS.” Hum Reprod 21 (2006): 2252–6.
Nestler, J.E., Jakubowicz, D.J., Evans, W.S., Pasquali, R. “Effects of metformin on spontaneous and clomiphene- induced ovulation in the polycystic ovary syndrome.” N Engl J Med 338 (1998): 1876–80.
De Leo, V., La Marca, A., Ditto, A., et al. “Effects of metformin on gonadotropin-induced ovulation in women with PCOS.” Fertil Steril 72 (1999): 282–5.
Larner, J. “Multiple pathways in insulin signalling: fitting the covalent and allosteric puzzle pieces together.” Endocr J 2 (1994): 167–71.
Evans, J.L., Heymann, C.J., Goldfine, I.D., Gavin, L.A. “Pharmacokinetics tolerability, and fructosamine lowering effect of a novel, controlled release formulation of alpha-lipoic acid.” Endocr Pract 8 (2002): 29–35.
Kim, M.S., Park, J.Y., Namkoong, C., et al. “Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP activated protein kinase.” Nat Med 10 (2004): 727–33.
Zacche, M.M., Caputo, L., Filippis, S., et al. “Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.” Gynecol Endocrinol 25 (2009): 508–13.
Papaleo, E., Unfer, V., Baillargeon, J.P., et al. “Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.” Gynecol Endocrinol 23 (2007): 700–3.
Papaleo, E., Unfer, V., Baillargeon, J.P., Chiu, TT. “Contribution of myo-inositol to reproduction.” Eur J Obstet Gynecol Reprod Biol 147 (2009): 120–3.
Gerli, S., Papaleo, E., Ferrari, A., Di Renzo, G.C. “Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS.” Eur Rev Med Pharmacol Sci 11 (2007): 347–54.
De Leo, V., La Marca, A., Petraglia, F. “Insuline lowering agents in the management of PCOS.” Endocr Rev 24 (2003): 633–67.
Glueck, C.J., Streicher, P., Wang, P. “Treatment of polycystic ovary syndrome with insulin lowering agents.” Expert Opin Pharmacother 8 (2002):1177–89.
Franks, S. “Genetic and environmental origins of obesity relevant to reproduction.” Rerod Biomed Online 12 (2006): 526–31.
GOST Style Citations
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)